Technology evaluation: DCVax, Northwest Biotherapeutics.
DCVax, a dendritic cell-based immunotherapy, is an active immunization platform being developed by Northwest Biotherapeutics for the potential treatment of multiple malignancies, including hormone-refractory metastatic prostate cancer, non-small-cell lung cancer, renal cancer and glioblastoma multiforme. The DCVax platform is tailored to a specific cancer type with either purified tumor-specific antigen or tumor cell extracts derived from patients at the time of resection. Phase I/II clinical trials of DCVax-Prostate have been completed, and phase III clinical trials have recently been initiated. DCVax-Brain is currently undergoing phase II clinical trials, and DCVax-Lung recently received approval from the US FDA for phase I clinical trials.
Knutson
Keith L
KL
University of Washington, Tumor Vaccine Group, Seattle 98195, USA. kknutson@u.washington.edu
D001932:Brain Neoplasms / Q000628:therapy; D019496:Cancer Vaccines / Q000009:adverse effects / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008175:Lung Neoplasms / Q000628:therapy; D008297:Male; D011471:Prostatic Neoplasms / Q000628:therapy
D019496:Cancer Vaccines